Exposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease
Authors
Keywords
Nintedanib, Idiopathic pulmonary fibrosis, Systemic sclerosis associated interstitial lung disease, Progressive fibrosing ILDs, Exposure-efficacy relationship, Rate of decline in FVC
Journal
RESPIRATORY MEDICINE
Volume -, Issue -, Pages 106369
Publisher
Elsevier BV
Online
2021-03-14
DOI
10.1016/j.rmed.2021.106369
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
- (2019) Sven Wind et al. CLINICAL PHARMACOKINETICS
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
- (2019) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
- (2019) Kevin R. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies
- (2019) Elizabeth T Thomas et al. BMJ Open
- Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
- (2018) Ulrike Schmid et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Hypersensitivity Pneumonitis: Radiologic Phenotypes are Associated with Distinct Survival Time and Pulmonary Function Trajectory
- (2018) Margaret L. Salisbury et al. CHEST
- Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
- (2017) Kristell Marzin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
- (2017) Luca Richeldi et al. THORAX
- Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
- (2016) Luca Richeldi et al. RESPIRATORY MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis
- (2014) Luca Richeldi et al. RESPIRATORY MEDICINE
- Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants
- (2013) Simon L F Walsh et al. THORAX
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
- (2011) Martin Bergstrand et al. AAPS Journal
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers
- (2011) Peter Stopfer et al. XENOBIOTICA
- Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
- (2009) E. J. Kim et al. EUROPEAN RESPIRATORY JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started